Galectin Therapeutics Inc. (GALT) vs Opus Genetics, Inc. (IRD)

Galectin Therapeutics Inc. and Opus Genetics, Inc. are both Biotechnology companies. Galectin Therapeutics Inc. and Opus Genetics, Inc. are of similar size ($405.2M and $399.4M). Galectin Therapeutics Inc. has the higher net margin (0.00% vs −1,091.8%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, Galectin Therapeutics Inc. leads on 7 and Opus Genetics, Inc. on 5.

Valuation

Metric GALT IRD Biotechnology median
P/E n/m n/m 7.88
P/S n/m 46.11 11.47
P/B n/m n/m 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales n/m 40.67 10.73
Earnings yield (11.03%) (27.10%) (28.84%)
Free cash flow yield (6.18%) (9.30%) (23.03%)

Profitability

Metric GALT IRD Biotechnology median
Gross margin 0.00% 100.00% 65.16%
Operating margin 0.00% (513.47%) 0.00%
Net margin 0.00% (1,091.82%) 0.00%
Free cash flow margin 0.00% (412.61%) 0.00%
Return on equity 21.69% (4,796.52%) (57.72%)
Return on assets (184.22%) (163.50%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric GALT IRD Biotechnology median
Revenue growth (TTM) — (36.09%) 5.64%
EPS growth (last fiscal year) 36.84% 62.79% —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric GALT IRD Biotechnology median
Debt to equity (0.76) (2.69) 0.00
Current ratio 0.10 12.19 4.73
Net debt to EBITDA (5.79) 1.17 0.96

Dividend

Metric GALT IRD Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric GALT IRD Biotechnology median
Market cap 399.36m 405.16m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack